<DOC>
	<DOCNO>NCT01726075</DOCNO>
	<brief_summary>To assess whether neuroprotective drug administer topically ( somatostatin brimonidine ) able prevent arrest development progression neurodegenerative change</brief_summary>
	<brief_title>Trial Assess Efficacy Neuroprotective Drugs Administered Topically Prevent Arrest Diabetic Retinopathy</brief_title>
	<detailed_description>To assess whether neuroprotective drug administer topically ( somatostatin brimonidine ) able prevent arrest development progression neurodegenerative change relate diabetic retinopathy .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Neuroprotective Agents</mesh_term>
	<criteria>1 . Patients type 2 diabetes mellitus 2 . Diabetes duration ≥ 5 year 3 . Aged 4575 yearsold 4 . ETDRS level &lt; 20 ( microaneurysms absent ) ( 50 % enrolled patient ) Or ETDRS level 20 35 presence least one microaneurysm Field 2 superior inferior arcade ( 50 % enrolled patient ) Study Eye determine Reading Centre . 5 . Informed Consent 1 . Previous laser photocoagulation 2 . Other disease may induce retinal degeneration ( e.g . glaucoma ) 3 . Subject refractive error ≥ ± 5 diopter 4 . Inadequate ocular medium and/ pupil dilatation permit good quality fundus photography . 5 . Renal failure ( creatinine &gt; 1.4 mg/dl ) 6 . HbA1C &gt; 10 % previous 6 month Screening 7 . Subjects take somatostatin brimonidine , indication , previous 3 month 8 . Subject condition situation may put subject significant risk , may confound study result may interfere significantly patient 's participation study . 9 . Pregnancy nurse 10 . Hypersensitivity active substance test excipients 11 . Subject receive systemic monoamine oxidase ( MAO ) inhibitor therapy antidepressant affect noradrenergic transmission ( e.g . tricyclic antidepressant mianserin )</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>diabetic retinopathy</keyword>
</DOC>